Labcorp Enables KEYTRUDA Access with FDA Diagnostic
BURLINGTON, N.C., April 22, 2026 Labcorp announced the nationwide availability of the FDA-approved PD-L1 IHC 22C3 pharmDx companion diagnostic,...
Ovarian Cancer
Advertisement
GSK Reports Strong ADC Data in Ovarian Cancer Study
London, United Kingdom | April 13, 2026 GSK plc has announced positive clinical data from its Phase 1 BEHOLD-1...
AbbVie Reports Strong Phase 2 Data in Ovarian Cancer
North Chicago, Illinois | April 12, 2026 AbbVie has announced late-breaking Phase 2 clinical trial results demonstrating strong efficacy...
Insilico Medicine Advances ISM6200 for Cancer Therapy
HONG KONG | April 10, 2026 Insilico Medicine has announced the nomination of ISM6200, a potential best-in-class selective NR3C1...
Merck Wins EU Approval for KEYTRUDA Combo in Ovarian Cancer
RAHWAY, N.J., April 2, 2026 Merck (MSD) has secured a major regulatory milestone as the European Commission approves KEYTRUDA®...
Advertisements
Zymeworks’ ZW191 Gets FDA Fast Track for Cancer
VANCOUVER, British Columbia, March 30, 2026 Zymeworks Inc. announced that the U.S. FDA has granted Fast Track designation to...
Myriad CDx Test Approved to Guide Ovarian Cancer Therapy
SALT LAKE CITY, March 17, 2026 Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Allarity Therapeutics Secures $20M to Advance Stenoparib
TARPON SPRINGS, Fla., March 6, 2026 Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the successful closing of...
Anixa CAR-T Breakthrough Highlighted at SCTR 2026
SAN JOSE, Calif., Feb. 23, 2026 — Anixa Biosciences announced that immunology leader Jose Conejo-Garcia, M.D., Ph.D., will keynote...
Anixa Advances CAR-T Dose Escalation in Ovarian Cancer
SAN JOSE, Calif., Feb. 9, 2026 — Anixa Biosciences reported encouraging survival observations from its ongoing Phase 1 ovarian...
Advertisement
